Author

N. Peekhaus

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:imaging· 1

Frequent Co-Authors

D. Ulmert· 3 shared R. Damoiseaux· 3 shared C. M. Storey· 2 shared D. Abou· 2 shared D. L. Thorek· 2 shared H. Lilja· 2 shared J. E. Park· 2 shared K. Herrmann· 2 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. Ulmert

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance

C. M. Storey, M. Altai, K. M. Lueckerath, W. Zedan, H. Zhu, M. Trajkovic-Arsic, J. E. Park, N. Peekhaus, J. Siveke, H. Lilljebjorn, D. Abou, H. L. Marks, E. Ulmert, H. Lilja, A. Ridley, , D. Ulmert

This paper develops a radio-theranostic approach targeting LRRC15 to image and treat cancer, showing tumor reduction and reversal of immunotherapy resistance.

bioRxiv · Jan 30, 2024 · PreprintPharmacology & Toxicology

Assessing Functional Androgen Receptor Pathway Activity in Response to Radiotherapy Using hK2-targeted PET Imaging

C. M. Storey, M. Altai, M. Bicak, D. R. Veach, K. Lueckerath, G. Adrian, M. R. McDevitt, T. Kalidindi, J. E. Park, K. Herrmann, D. Abou, W. Zedan, N. Peekhaus, R. J. Klein, R. Damoiseaux, , D. Ulmert

This study evaluates if [89Zr]11B6-PET can detect EBRT-induced AR pathway activation in PCa using hK2 as a biomarker.

bioRxiv · Jun 23, 2022 · PreprintCancer Biology

Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy

M. Bicak, K. Lueckerath, T. Kalidindi, S.-E. Strand, M. Morris, C. Radu, R. Damoiseaux, N. Peekhaus, A. Ho, D. V. Veach, A.-C. Malmborg Hager, S. M. Larson, H. Lilja, M. R. McDevitt, R. J. Klein, D. Ulmert

The paper evaluates enhanced alpha-radioimmunotherapy for prostate cancer using [225Ac]hu11B6-IgG3 and analyzes genomic changes in resistant tumors.

bioRxiv · Sep 2, 2019Cancer Biology